FDA’s Woodcock calls to cut clinical costs via new efficiencies

By Zachary Brennan contact

- Last updated on GMT

FDA’s Woodcock calls to cut clinical costs via new efficiencies

Related tags: Clinical trial

As the cost of clinical trials continues to grow, Janet Woodcock, director of the Center for Drug Evaluation and Research at the FDA told Senators earlier this week that there are “ways to greatly improve clinical trial efficiency,” and cut costs through the use of master protocols and real-world data.

Drug developers spend millions of dollars planning a trial, often times with CRO partners, developing an elaborate infrastructure to run it, finding and enlisting investigators, conducting the trials, and managing the data.

But, as Woodcock noted, “Each time a new drug is tested, the process is repeated, at great expense, only to dismantle the infrastructure when the study is completed. We believe that there are ways to greatly improve clinical trial efficiency, such as widespread use of clinical trial networks and master protocols, and we would like to work with you to examine those possibilities​.”

The FDA may look to take a page out of the book of the UK’s NIHR (National Institute for Health Research) clinical research network, which recently restructured​, and helps to support thousands of trials per year.


In addition to the master protocol idea for trials, Woodcock called to enhance the science of identifying and evaluating the utility of biomarkers, which can predict and evaluate the effects of proposed drugs before clinical testing and in people.

However, biomarkers based on new scientific understanding have been slow to come into clinical use, largely because the evidence supporting their validity has been lacking. The lack of new, well-understood biomarkers also impacts drug development, these new tests could speed evaluation of drug performance, including drug safety, and prediction of effectiveness. Similar to the problems with clinical trials, the scientific infrastructure for evaluating the validity of new biomarkers has not kept pace with the need for this activity​,” Woodcock added.

She also clarified that the FDA recognizes that there is still confusion about how new biomarkers can be qualified as some sponsors believe that many biomarkers are “stalled​” in the qualification process.

The actual case is that most of the programs in the biomarker qualification process are still in the evidence-gathering stage—which may take considerable time due to the need for more development work within the scientific community​,” Woodcock said.

Real-World Data

As the FDA approves therapies faster than any other developed country and more quickly than ever before, the agency will look to harness big data to track the safety of new drugs.

I have aggressively developed FDA’s Sentinel Initiative, a national electronic system that is transforming FDA’s ability to track the safety of drugs and biologics once they reach the market. Sentinel enables FDA to actively query diverse health care data sources—such as electronic health record systems, administrative and insurance claims databases, and registries—to evaluate possible medical product safety issues quickly and securely​,” Woodcock said.

But she also noted that “the science of using evidence from clinical experience to establish product effectiveness…is still in its infancy. So we must first develop the methodologies needed to harness its promise​.”

Related news

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us


View more